New Funding Opportunities Center on Coordinating Centers

Funding News Edition: September 07, 2022
See more articles in this edition

Through three new funding opportunity announcements (FOAs), NIAID seeks to establish the following Centers. We provide brief overviews here and encourage you to read the FOAs and related Questions and Answers.

Allergy and Asthma Statistical and Clinical Coordinating Center (AA-SCCC) (U01, Clinical Trial Not Allowed)

  • Project Period: 5 years
  • NIAID intends to commit up to $9 million in FY 2023 to fund one award.
  • Application Due Date: November 30, 2022
  • Read Questions and Answers for RFA-AI-22-054 for additional information.
  • Direct inquiries to the scientific/research contact Dr. Gang Dong at gdong@nih.niaid.gov or 240-627-3508.
  • For questions specific to peer review, contact Dr. Lindsey Pujanandez at lindsey.pujanandez@nih.gov or 301-761-7830.

This FOA seeks applications for an Allergy and Asthma Statistical and Clinical Coordinating Center (AA-SCCC) to provide a broad range of support critical for the design, development, execution, and analysis of clinical research in allergic diseases and asthma.

For a list of major clinical research programs to be supported by the AA-SCCC, go to RFA-AI-22-054 Research Studies To Be Supported by the AA-SCCC. The AA-SCCC may also support investigator-initiated clinical trials, and other clinical trial/study activities funded by NIAID, e.g., integrated studies of underlying mechanisms, studies to identify and validate surrogates/biomarkers.

Transplantation Statistical and Clinical Coordinating Center (T-SCCC) (U01, Clinical Trial Not Allowed)

  • Project Period: 5 years
  • NIAID intends to commit up to $9 million in FY 2023 to fund a single award.
  • Application Due Date: November 30, 2022
  • Check Questions and Answers for RFA-AI-22-057 for additional information.
  • Direct inquiries to the scientific/research contact Deborah Hayes at dhayes@niaid.nih.gov or 240-627-3496.
  • For questions specific to peer review, contact Dr. Tara Capece at Tara.capece@nih.gov or 301-761-7854.

The purpose of this FOA is to solicit applications for a Transplantation Statistical and Clinical Coordinating Center (T-SCCC) to provide a broad range of support critical for the design, development, execution, and analysis of clinical research carried out by multiple NIAID-supported programs in transplantation.

The scope is to support the study teams with statistical design and analysis, protocol development, and final analysis of study findings. In addition, the T-SCCC will support the mechanistic studies by providing establishment and maintenance of a biospecimen tracking database; biospecimen labeling, shipping, tracking; and kits and/or bulk supplies for specimen collection. Finally, the T-SCCC will work collaboratively with the Clinical Data and Safety and Monitoring Center that will provide data management for the transplantation clinical trials. The types of research for which support will be provided include clinical trials, integrated studies of underlying mechanisms, clinical studies (e.g., longitudinal studies, genetic studies), and studies to identify and validate surrogates/biomarkers.

For a list of research studies to be supported by the T-SCCC, go to RFA-AI-22-057 Research Studies To Be Supported by the T-SCCC.

National Institute of Allergy and Infectious Diseases (NIAID) Clinical Data and Safety Management Center (CDSMC) (U01, Clinical Trial Not Allowed)

The overall objective of the CDSMC is to provide coordination and oversight for multiple activities in service to clinical research and mechanistic studies supported by NIAID, e.g., data collection, data management, reporting and processing, safety and pharmacovigilance, data support for Data and Safety Monitoring Boards meetings, and an Electronic Specimen Tracking process for both domestic and/or international research.

The primary scientific areas supported through the functions of the CDSMC include asthma and allergic diseases; autoimmune disorders; immune-mediated consequences of allotransplantation and possibly xenotransplantation; primary immune deficiency disorders; and other immune system disorders and treatments to enhance immune functions. Other NIAID-supported research may use the functions within the CDSMC under a public health emergency.

See the FOA for information on Functional Structure, Additional Resources Provided by NIAID, and more.

Contact Us

Email us at deaweb@niaid.nih.gov for help navigating NIAID’s grant and contract policies and procedures.

Content last reviewed on